Article

Researchers on Verge of Breakthrough New Class of Cancer Drugs

Inhibiting a previously undruggable protein holds promise for treatment of numerous types of cancer.

Blocking a specific protein linked with cancer growth may lead to the development of a breakthrough new class of oncology drugs, a recent study found.

The study, published in the current issue of ACS Chemical Biology, evaluated 6 chemical compounds that inhibit the so-called “oncoprotein” HuR, which binds to RNA and promotes tumor growth.

"These are the first reported small-molecule HuR inhibitors that competitively disrupt HuR-RNA binding and release the RNA, thus blocking HuR function as a tumor-promoting protein," corresponding author Liang Xu said in a press release.

Read more at Specialty Pharmacy TImes: http://bit.ly/1aUR8oP

Related Videos
Nini Wu, MD, Navista
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Lalan Wilfong, MD
Katherine Baker, MD, MMHC
Nini Wu, MD, MBA
Andrew Chapman, DO
Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo